BioCardia, Inc. (BCDA)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
BioCardia, Inc. (BCDA) with AI Score 45/100 (Weak). BioCardia, Inc. is a clinical-stage regenerative medicine company focused on developing cell-based therapies for cardiovascular and pulmonary diseases. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 15, 2026BioCardia, Inc. (BCDA) Healthcare & Pipeline Overview
BioCardia, Inc. is a clinical-stage biotechnology firm specializing in regenerative medicine for cardiovascular and pulmonary diseases. Their primary focus is the CardiAMP Cell Therapy System, a novel approach to treating heart failure and chronic myocardial ischemia, positioning them in a competitive landscape of cell-based therapeutics.
Investment Thesis
BioCardia, Inc. presents a notable research candidate within the regenerative medicine sector, primarily driven by its CardiAMP Cell Therapy System targeting heart failure and chronic myocardial ischemia. The company's allogeneic cell therapy platform, currently in Phase I/II trials, offers additional upside potential. Key value drivers include successful clinical trial outcomes, regulatory approvals, and strategic partnerships. The company's market capitalization is approximately $0.01 billion. A potential risk factor is the inherent uncertainty in clinical trial results and regulatory approval timelines, which could impact the company's valuation and future prospects. As of 2026-03-15, investors should closely monitor clinical trial data releases and regulatory updates to assess the viability of BioCardia's therapeutic candidates.
Based on FMP financials and quantitative analysis
Key Highlights
- BioCardia's lead therapeutic candidate is the CardiAMP Cell Therapy System, targeting heart failure and chronic myocardial ischemia.
- The company is developing an allogeneic cell therapy platform, currently in Phase I/II trials for ischemic systolic heart failure.
- BioCardia offers the Helix biotherapeutic delivery system for precise delivery of therapeutics into the heart muscle.
- The company's market capitalization is approximately $0.01 billion as of 2026-03-15.
- BioCardia has a beta of 0.55, indicating lower volatility compared to the overall market.
Competitors & Peers
Strengths
- Proprietary cell therapy technology (CardiAMP).
- Innovative drug delivery systems (Helix).
- Experienced management team.
- Focus on unmet needs in cardiovascular and pulmonary diseases.
Weaknesses
- Clinical-stage company with no currently approved products.
- Limited financial resources.
- Dependence on successful clinical trial outcomes.
- Small number of employees (17).
Catalysts
- Upcoming: Data release from ongoing clinical trials of CardiAMP Cell Therapy System.
- Upcoming: Potential regulatory approval decisions for CardiAMP in specific indications.
- Ongoing: Advancement of allogeneic cell therapy platform through Phase I/II trials.
- Ongoing: Strategic partnerships and collaborations with pharmaceutical companies.
Risks
- Potential: Unsuccessful clinical trial results for CardiAMP or allogeneic cell therapies.
- Potential: Regulatory delays or rejection of therapeutic candidates.
- Potential: Competition from other regenerative medicine companies.
- Ongoing: Limited financial resources and dependence on external funding.
Growth Opportunities
- Expansion of CardiAMP Cell Therapy: BioCardia has the opportunity to expand the application of its CardiAMP Cell Therapy System to additional indications within cardiovascular disease. The market for heart failure treatments is substantial, with millions of patients worldwide. Successful clinical trials and regulatory approvals for new indications could significantly increase the market potential for CardiAMP. Timeline: Ongoing clinical trials with potential data releases in the next 12-24 months.
- Advancement of Allogeneic Cell Therapy Platform: The company's allogeneic cell therapy platform, currently in Phase I/II trials, represents a significant growth opportunity. Allogeneic therapies offer advantages in terms of scalability and cost compared to autologous therapies. Positive clinical trial results could lead to partnerships and further development of this platform. Timeline: Phase II data expected within the next 18-36 months.
- Strategic Partnerships and Collaborations: BioCardia can pursue strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its therapeutic candidates. Collaborations can provide access to funding, expertise, and distribution networks. The market for partnering in regenerative medicine is active, with numerous deals occurring each year. Timeline: Ongoing discussions with potential partners.
- Expansion of Delivery System Technologies: The Helix biotherapeutic delivery system and Morph deflectable guides and sheaths offer opportunities for expansion into new therapeutic areas and partnerships with other companies developing cardiovascular therapies. These delivery systems can enhance the precision and efficacy of various treatments. Timeline: Ongoing development and potential partnerships in the next 12-24 months.
- Geographic Expansion: BioCardia has the potential to expand its operations and commercialization efforts into new geographic markets, particularly in Europe and Asia. These markets offer significant growth opportunities for regenerative medicine products. Regulatory approvals and strategic partnerships will be key to successful geographic expansion. Timeline: Potential expansion into Europe and Asia within the next 3-5 years.
Opportunities
- Expansion of CardiAMP to new indications.
- Strategic partnerships with larger pharmaceutical companies.
- Advancement of allogeneic cell therapy platform.
- Geographic expansion into Europe and Asia.
Threats
- Competition from other regenerative medicine companies.
- Regulatory hurdles and delays.
- Unsuccessful clinical trial results.
- Changes in healthcare reimbursement policies.
Competitive Advantages
- Proprietary Cell Therapy Technology: The CardiAMP Cell Therapy System and allogeneic cell therapy platform are protected by patents and represent a unique approach to regenerative medicine.
- Proprietary Delivery Systems: The Helix biotherapeutic delivery system and Morph deflectable guides and sheaths provide a competitive advantage in the precise delivery of therapeutics.
- Clinical Trial Data: Positive clinical trial data provides a barrier to entry for competitors and supports the efficacy and safety of BioCardia's therapies.
- Strategic Partnerships: Collaborations with leading medical centers and pharmaceutical companies enhance BioCardia's credibility and market access.
About BCDA
BioCardia, Inc., headquartered in Sunnyvale, California, is a clinical-stage regenerative medicine company dedicated to developing innovative cellular and cell-derived therapeutics. The company focuses on addressing significant unmet needs in the treatment of cardiovascular and pulmonary diseases. BioCardia's lead therapeutic candidate is the CardiAMP Cell Therapy System, which is designed for the treatment of heart failure and chronic myocardial ischemia. This system utilizes a patient's own cells to promote cardiac regeneration and improve heart function. In addition to CardiAMP, BioCardia is developing an allogeneic cell therapy platform for both cardiac and pulmonary conditions. This platform involves culture-expanded, bone marrow-derived mesenchymal cells and is currently in Phase I/II clinical trials for ischemic systolic heart failure. BioCardia also offers the Helix biotherapeutic delivery system, a proprietary technology that enables precise delivery of therapeutics into the heart muscle using a penetrating helical needle. Complementing this, they provide Morph deflectable guides and sheaths, enhancing the precision and control of therapeutic delivery. Founded with the vision of transforming cardiovascular and pulmonary care through regenerative medicine, BioCardia continues to advance its pipeline of innovative therapies and delivery systems.
What They Do
- Develops the CardiAMP Cell Therapy System for heart failure and chronic myocardial ischemia.
- Creates allogeneic cell therapy for cardiac and pulmonary diseases.
- Offers the Helix biotherapeutic delivery system for precise drug delivery to the heart.
- Provides Morph deflectable guides and sheaths for enhanced therapeutic delivery.
- Conducts clinical trials to evaluate the safety and efficacy of its therapies.
- Seeks regulatory approvals for its therapeutic candidates.
- Engages in research and development to advance regenerative medicine.
Business Model
- Develops and patents cell-based therapies and delivery systems.
- Conducts clinical trials to demonstrate efficacy and safety.
- Seeks regulatory approval from agencies like the FDA.
- Out-licenses or partners with larger pharmaceutical companies for commercialization.
Industry Context
BioCardia operates within the rapidly evolving regenerative medicine sector, which is experiencing significant growth due to advancements in cell therapies and increasing demand for innovative treatments for cardiovascular and pulmonary diseases. The market for cell-based therapies is projected to reach billions of dollars in the coming years. BioCardia competes with other biotechnology companies developing similar regenerative medicine products. The competitive landscape includes companies focusing on cell therapies, gene therapies, and tissue engineering. BioCardia's proprietary delivery systems, such as the Helix system, provide a potential competitive advantage in the precise delivery of therapeutics.
Key Customers
- Hospitals and medical centers specializing in cardiology and pulmonology.
- Cardiologists and pulmonologists treating patients with heart failure and pulmonary diseases.
- Patients suffering from heart failure, chronic myocardial ischemia, and other cardiovascular and pulmonary conditions.
- Pharmaceutical companies seeking innovative drug delivery systems.
Financials
Chart & Info
BioCardia, Inc. (BCDA) stock price: Price data unavailable
Latest News
-
12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga · Mar 24, 2026
-
Earnings Scheduled For March 24, 2026
benzinga · Mar 24, 2026
-
BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026
globenewswire.com · Mar 19, 2026
-
Earnings Scheduled For November 12, 2025
benzinga · Nov 12, 2025
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for BCDA.
Price Targets
Wall Street price target analysis for BCDA.
MoonshotScore
What does this score mean?
The MoonshotScore rates BCDA's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Latest News
12 Health Care Stocks Moving In Tuesday's After-Market Session
Earnings Scheduled For March 24, 2026
BioCardia to Host 2025 Financial Results and Corporate Update Conference Call on March 24, 2026
Earnings Scheduled For November 12, 2025
Leadership: Peter A. Altman
CEO
Peter A. Altman serves as the CEO of BioCardia, Inc., bringing extensive experience in the biotechnology and medical device industries. His background includes leadership roles in various companies focused on developing and commercializing innovative healthcare technologies. Altman's expertise spans strategic planning, product development, and commercial operations. He has a proven track record of driving growth and creating value in the healthcare sector. His leadership is instrumental in guiding BioCardia's strategic direction and advancing its pipeline of regenerative medicine therapies.
Track Record: Under Peter Altman's leadership, BioCardia has focused on advancing its CardiAMP Cell Therapy System through clinical trials. He has overseen the development of the company's allogeneic cell therapy platform and the expansion of its delivery system technologies. Altman has also been instrumental in securing partnerships and collaborations to support BioCardia's growth initiatives. He manages a team of 17 employees.
BCDA Healthcare Stock FAQ
What does BioCardia, Inc. do?
BioCardia, Inc. is a clinical-stage regenerative medicine company focused on developing cell-based therapies for cardiovascular and pulmonary diseases. Their primary focus is the CardiAMP Cell Therapy System, which aims to treat heart failure and chronic myocardial ischemia by using a patient's own cells to regenerate heart tissue. The company also develops allogeneic cell therapies and proprietary delivery systems like the Helix system to improve therapeutic precision and efficacy. BioCardia seeks to address unmet needs in treating cardiovascular and pulmonary conditions through innovative regenerative medicine approaches.
What do analysts say about BCDA stock?
As of 2026-03-15, formal analyst ratings for BCDA are not available in the provided data. However, given its clinical-stage nature and focus on regenerative medicine, potential investors should closely monitor clinical trial results, regulatory milestones, and financial performance. The company's valuation will likely be heavily influenced by the success of its CardiAMP Cell Therapy System and the advancement of its allogeneic cell therapy platform. Investors should conduct their own due diligence and consider the inherent risks associated with biotechnology companies in the clinical development phase.
What are the main risks for BCDA?
The primary risks for BioCardia, Inc. include the uncertainty of clinical trial outcomes for its CardiAMP Cell Therapy System and allogeneic cell therapy platform. Negative or inconclusive trial results could significantly impact the company's valuation and future prospects. Regulatory hurdles and potential delays in obtaining approvals from agencies like the FDA also pose a risk. Competition from other companies in the regenerative medicine space, as well as the company's limited financial resources, further contribute to the risk profile. Investors should carefully evaluate these factors before considering an investment in BCDA.
How does BioCardia, Inc. navigate regulatory approval processes?
BioCardia, Inc. navigates regulatory approval processes by conducting rigorous clinical trials to demonstrate the safety and efficacy of its therapeutic candidates. The company works closely with regulatory agencies like the FDA to ensure compliance with all applicable regulations and guidelines. BioCardia's strategy involves submitting comprehensive data packages, including preclinical and clinical data, to support its applications for regulatory approval. The company also engages in ongoing communication with regulatory agencies to address any questions or concerns that may arise during the review process. Successful navigation of these processes is crucial for bringing BioCardia's therapies to market.
What revenue streams does BioCardia, Inc. have in healthcare?
As a clinical-stage company, BioCardia, Inc. currently does not have significant revenue streams from commercial product sales. The company's primary sources of funding include venture capital, grants, and potential future partnerships or licensing agreements. If BioCardia successfully obtains regulatory approval for its CardiAMP Cell Therapy System or other therapeutic candidates, potential revenue streams could include product sales, royalties from out-licensing agreements, and revenue from strategic collaborations with pharmaceutical companies. The timing and magnitude of these revenue streams are dependent on the successful completion of clinical trials and regulatory approval processes.
What are the key factors to evaluate for BCDA?
BioCardia, Inc. (BCDA) currently holds an AI score of 45/100, indicating low score. Key strength: Proprietary cell therapy technology (CardiAMP).. Primary risk to monitor: Potential: Unsuccessful clinical trial results for CardiAMP or allogeneic cell therapies.. This is not financial advice.
How frequently does BCDA data refresh on this page?
BCDA prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven BCDA's recent stock price performance?
Recent price movement in BioCardia, Inc. (BCDA) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary cell therapy technology (CardiAMP).. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on provided sources and may not reflect the most recent developments.
- AI analysis pending may provide further insights.